Press Releases PainReform Ltd.

Equities

PRFX

IL0011651580

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-22 pm EDT			5-day change	1st Jan Change
0.75 ^USD	0.00%		-6.26%	-72.73%

Apr. 16	PainReform Prices $4 Million Offering; Shares Tumble Pre-Bell	MT
Apr. 09	Painreform Ltd. Announces Groundbreaking Results from New Studies Demonstrating the Superior In-Vitro Release Rates of PRF-110	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

PAINREFORM : CONDENSED FINANCIAL STATEMENTS - Form 6-K	May. 15	PU
PainReform Provides Business Update for the First Quarter of 2024	May. 15	AQ
PainReform : CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com	May. 08	PU
PainReform Announces Closing of $4 Million Public Offering	Apr. 18	AQ
PainReform Announces Pricing of $4 Million Public Offering	Apr. 16	AQ
PainReform : CEO IlanHadar Interviewed on “The Big Biz Show”	Apr. 14	PU
PainReform : Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions	Apr. 09	PU
PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy	Apr. 02	AQ
PainReform : NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS - Form 6-K	Mar. 07	PU
PainReform : Investors Presentation – March 2024	Mar. 03	PU
PainReform Provides Year-End Business Update	Mar. 01	AQ
PainReform to Present at the Microcap Conference in Atlantic City	Jan. 22	NE
PainReform to Present at the Microcap Conference in Atlantic City	Jan. 22	AQ
PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief	Jan. 03	AQ
PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds	Dec. 26	AQ
PainReform : Condensed Statements of Changes in Shareholders’ Equity - Form 6-K	Nov. 15	PU
PainReform Provides Business Update for the Third Quarter of 2023	Nov. 15	AQ
PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File	23-09-11	AQ
PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary	23-09-07	AQ
PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City	23-09-05	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases PainReform Ltd.

Equities

PRFX

IL0011651580

Press Releases

Filters